Erythropoietin and protection of renal function in cardiac surgery (the EPRICS trial)

Anesthesiology

Volumn 121, Issue 3, 2014, Pages 582-590

  Dardashti, Alain ^a   Ederoth, Per ^a   Algotsson, Lars ^a   Brondén, Björn ^a   Grins, Edgars ^a   Larsson, Mårten ^a   Nozohoor, Shahab ^a   Zinko, Galyna ^a   Bjursten, Henrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYSTATIN C; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UREA; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SINGLE DRUG DOSE; ACUTE KIDNEY INJURY; MIDDLE AGED; PROSPECTIVE STUDY;

ACUTE KIDNEY INJURY; AGED; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 84921668873     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000321     Document Type: Article

References (47)

1. Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, Bihorac A: Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation 2009; 119:2444-53.
2. Lassnigg A, Schmid ER, Hiesmayr M, Falk C, Druml W, Bauer P, Schmidlin D: Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: Do we have to revise current definitions of acute renal failure? Crit Care Med 2008; 36:1129-37.
3. Brown JR, Cochran RP, Dacey LJ, Ross CS, Kunzelman KS, Dunton RF, Braxton JH, Charlesworth DC, Clough RA, Helm RE, Leavitt BJ, Mackenzie TA, O'Connor GT; Northern New England Cardiovascular Disease Study Group: Perioperative increases in serum creatinine are predictive of increased 90-day mortality after coronary artery bypass graft surgery. Circulation 2006; 114(1 suppl):1409-13.
4. Brown JR, Cochran RP, MacKenzie TA, Furnary AP, Kunzelman KS, Ross CS, Langner CW, Charlesworth DC, Leavitt BJ, Dacey LJ, Helm RE, Braxton JH, Clough RA, Dunton RF, O'Connor GT; Northern New England Cardiovascular Disease Study Group: Long-term survival after cardiac surgery is predicted by estimated glomerular filtration rate. Ann Thorac Surg 2008; 86:4-11.
5. Dardashti A, Ederoth P, Algotsson L, Brondén B, Bjursten H: Incidence, dynamics, and prognostic value of acute kidney injury for death after cardiac surgery. J Thorac Cardiovasc Surg 2014; 147:800-7.
6. Zacharias M, Mugawar M, Herbison GP, Walker RJ, Hovhannisyan K, Sivalingam P, Conlon NP: Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev 2013; 9:CD003590.
7. Bahlmann FH, Fliser D: Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009; 18:15-20.
8. Moore E, Bellomo R: Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care 2011; 1:3.
9. Kiris I, Kapan S, Kilbas A, Yilmaz N, Altuntas I, Karahan N, Okutan H: The protective effect of erythropoietin on renal injury induced by abdominal aortic-ischemia-reperfusion in rats. J Surg Res 2008; 149:206-13.
10. Moriyama M, Tanaka T, Suzuki K: [Renal protective effects of erythropoietin on ischemic reperfusion injury]. Hinyokika Kiyo 2010; 56:473-9.
11. Phillips CK, Hruby GW, Mirabile G, Motamedinia P, Lehman DS, Okhunov Z, Singh H, Schwartz M, Benson MC, Landman J: Erythropoietin-induced optimization of renal function after warm ischemia. J Endourol 2009; 23:359-65.
12. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC: Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69:1806-13.
13. Vesey DA, Cheung C, Pat B, Endre Z, Gobé G, Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19:348-55.
14. Simon F, Scheuerle A, Calzia E, Bassi G, Oter S, Duy CN, Kick J, Brückner UB, Radermacher P, Schelzig H: Erythropoietin during porcine aortic balloon occlusion-induced ischemia/reperfusion injury. Crit Care Med 2008; 36:2143-50.
15. Stevens RD, Bhardwaj A: Eryrthropoietin and the promise of ischemic multiorgan protection. Crit Care Med 2008; 36:2446-7.
16. Oh SW, Chin HJ, Chae DW, Na KY: Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci 2012; 27:506-11.
17. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY: Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: A pilot study. Am J Nephrol 2009; 30:253-60.
18. Tasanarong A, Duangchana S, Sumransurp S, Homvises B, Satdhabudha O: Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinaseassociated lipocalin in patients undergoing cardiac surgery: A randomized, double-blind controlled trial. BMC Nephrol 2013; 14:136.
19. Hand CC, Brines M: Promises and pitfalls in erythopoietinmediated tissue protection: Are nonerythropoietic derivatives a way forward? J Investig Med 2011; 59:1073-82.
20. Poulsen TD, Andersen LW, Steinbrüchel D, Gøtze JP, Jørgensen OS, Olsen NV: Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. J Cardiothorac Vasc Anesth 2009; 23:316-23.
21. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM: Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77:1020-30.
22. De-Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P: Epoetin administrated after cardiac surgery: Effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 2012; 13:132.
23. Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL: Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: A double blind, randomized clinical trial of efficacy and safety. Crit Care 2013; 17:R254.
24. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL: Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011; 115:929-37.
25. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C; EPO Stroke Trial Group: Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40:e647-56.
26. Bagshaw SM, Gibney RT: Conventional markers of kidney function. Crit Care Med 2008; 36(4 suppl):S152-8.
27. Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanandam V, Kasza KE, O'Connor MF, Konczal DJ, Trevino S, Devarajan P, Murray PT: Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 2008; 74:1059-69.
28. Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, Haase M: Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery-A prospective cohort study. Crit Care Med 2009; 37:553-60.
29. Royakkers AA, van-Suijlen JD, Hofstra LS, Kuiper MA, Bouman CS, Spronk PE, Schultz MJ: Serum cystatin C-A useful endogenous marker of renal function in intensive care unit patients at risk for or with acute renal failure? Curr Med Chem 2007; 14:2314-7.
30. Delanaye P, Lambermont B, Chapelle JP, Gielen J, Gerard P, Rorive G: Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units. Intensive Care Med 2004; 30:980-3.
31. Brondén B, Eyjolfsson A, Blomquist S, Dardashti A, Ederoth P, Bjursten H: Evaluation of cystatin C with iohexol clearance in cardiac surgery. Acta Anaesthesiol Scand 2011; 55:196-202.
32. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A: Acute kidney injury: A relevant complication after cardiac surgery. Ann Thorac Surg 2011; 92:1539-47.
33. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup: Acute renal failure- Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-12.
34. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.
35. Fossati P, Prencipe L, Berti G: Enzymic creatinine assay: A new colorimetric method based on hydrogen peroxide measurement. Clin Chem 1983; 29:1494-6.
36. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia- reperfusion. J Am Soc Nephrol 2004; 15:2115-24.
37. Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D: Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 2006; 21:330-6.
38. Sølling C, Christensen AT, Krag S, Frøkiaer J, Wogensen L, Krog J, Tønnesen EK: Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand 2011; 55:185-95.
39. Sølling C, Christensen AT, Nygaard U, Krag S, Frøkiaer J, Wogensen L, Krog J, Tønnesen EK: Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia. Acta Anaesthesiol Scand 2011; 55:411-21.
40. Landoni G, Fochi O, Tritapepe L, Guarracino F, Belloni I, Bignami E, Zangrillo A: Cardiac protection by volatile anesthetics. A review. Minerva Anestesiol 2009; 75:269-73.
41. Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, Turina MI, von Segesser LK, Pasch T, Spahn DR, Zaugg M: Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: A double-blinded, placebo-controlled, multicenter study. Anesthesiology 2003; 98:1315-27.
42. Wong GT, Huang Z, Ji S, Irwin MG: Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: A randomized trial. J Cardiothorac Vasc Anesth 2010; 24:790-6.
43. Ristikankare A, Pöyhiä R, Kuitunen A, Skrifvars M, Hämmäinen P, Salmenperä M, Suojaranta-Ylinen R: Serum cystatin C in elderly cardiac surgery patients. Ann Thorac Surg 2010; 89:689-94.
44. Spahillari A, Parikh CR, Sint K, Koyner JL, Patel UD, Edelstein CL, Passik CS, Thiessen-Philbrook H, Swaminathan M, Shlipak MG; TRIBE-AKI Consortium: Serum cystatin C- versus creatinine-based definitions of acute kidney injury following cardiac surgery: A prospective cohort study. Am J Kidney Dis 2012; 60:922-9.
45. Kato M, Sawada T, Kita J, Shimoda M, Kubota K: Erythropoietin ameliorates early ischemia-reperfusion injury following the Pringle maneuver. World J Gastroenterol 2010; 16: 4838-45.
46. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y, Kobayashi Y, Takeyama Y, Kobayashi N, Yoshimura N, Akazawa K, Aizawa Y; EPO/AMI-I Pilot Study Researchers: Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction-Randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010; 74:1415-23.
47. Mocini D, Muso P, Guendouz E, De Marco L, Mele L, Cini R, Sordini P, Alois A, Costantino A, Arima S, Gentili C, Santini M: Endogenous erythropoietin and a single bolus of 40, 000 IU of epoetin α do not protect the heart from ischaemiareperfusion injury during extracorporeal circulation for cardiac surgery. Perfusion 2008; 23:187-92.